Campbell Newman Asset Management Inc Eagle Pharmaceuticals, Inc. Transaction History

Campbell Newman Asset Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 19, 2021	SELL	$40.32 - $50.97 $427,956 - $540,995	-10,614 Closed	0 $0
Q4 2020 Feb 01, 2021	BUY	$41.72 - $51.34 $33,083 - $40,712	793 Added 8.07%	10,614 $494,000
Q3 2020 Oct 20, 2020	BUY	$37.02 - $51.28 $6,552 - $9,076	177 Added 1.84%	9,821 $417,000
Q2 2020 Jul 27, 2020	BUY	$43.24 - $55.02 $4,107 - $5,226	95 Added 0.99%	9,644 $463,000
Q1 2020 Apr 27, 2020	SELL	$34.37 - $60.07 $15,741 - $27,512	-458 Reduced 4.58%	9,549 $439,000
Q4 2019 Jan 22, 2020	SELL	$54.32 - $64.31 $1,086 - $1,286	-20 Reduced 0.2%	10,007 $601,000
Q3 2019 Oct 23, 2019	SELL	$53.25 - $59.98 $4,313 - $4,858	-81 Reduced 0.8%	10,027 $567,000
Q2 2019 Jul 24, 2019	BUY	$46.61 - $58.45 $31,275 - $39,219	671 Added 7.11%	10,108 $563,000
Q1 2019 Apr 09, 2019	BUY	$38.66 - $51.82 $9,046 - $12,125	234 Added 2.54%	9,437 $476,000
Q4 2018 Jan 18, 2019	BUY	$36.72 - $67.73 $35,434 - $65,359	965 Added 11.71%	9,203 $371,000
Q3 2018 Oct 15, 2018	BUY	$66.65 - $83.86 $28,659 - $36,059	430 Added 5.51%	8,238 $571,000
Q2 2018 Jul 25, 2018	BUY	$51.25 - $76.62 $197,517 - $295,293	3,854 Added 97.47%	7,808 $591,000
Q1 2018 Apr 25, 2018	BUY	$52.16 - $66.86 $10,536 - $13,505	202 Added 5.38%	3,954 $208,000
Q4 2017 Jan 25, 2018	BUY	$49.6 - $60.87 $186,099 - $228,384	3,752 New	3,752 $200,000
Q3 2017 Oct 11, 2017	SELL	$46.62 - $60.36 $125,547 - $162,549	-2,693 Closed	0 $0
Q2 2017 Aug 09, 2017	BUY	N/A	2,693	2,693 $212,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $8.46M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Campbell Newman Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Campbell Newman Asset Management Inc with notifications on news.